GAMMA Investing
CTNM icon

GAMMA Investing’s Contineum Therapeutics CTNM Stock Holding History

GAMMA Investing’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$550 Buy
+41
New +$611 ﹤0.01% 4196
2025
Q3 		– Sell
-60
Closed -$238 – 3938
2025
Q2 		$238 Sell
60
-122
-67% -$530 ﹤0.01% 3709
2025
Q1 		$1.27K Buy
182
+102
+128% +$928 ﹤0.01% 3513
2024
Q4 		$1.17K Buy
+80
New +$1.27K ﹤0.01% 3378

Other funds holding CTNM

Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Red Tree Management
Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Independent Financial Group
Independent Financial Group San Diego, California $5.51B AUM 33.51% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return
GF Fund Management
GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Torren Management
Torren Management San Diego, California $201M AUM 16.25% 1-Year Est. Return

GAMMA Investing's CTNM Position: Q3 2026 in Review

GAMMA Investing opened a new position in Contineum Therapeutics (CTNM) in Q3 2026: 41 shares worth $550. The stake represents ﹤0.01% of the portfolio and ranks #4196 among its holdings. This is a return to the name: GAMMA Investing previously reported a position in CTNM as recently as Q2 2025.

GAMMA Investing first reported a position in CTNM in Q4 2024 and has held it in 4 quarters since. The position peaked at $1.27K in Q1 2025. 15 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.

  • GAMMA Investing held 41 shares of Contineum Therapeutics worth $550 as of Q3 2026.
  • Contineum Therapeutics was a new GAMMA Investing position in Q3 2026.
  • Contineum Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #4196 holding.
  • GAMMA Investing first reported a position in Contineum Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • GAMMA Investing's Contineum Therapeutics position peaked at $1.27K in Q1 2025.
  • 15 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.